ZFIN ID: ZDB-FISH-150901-25105
Fish name: nz4Tg
Genotype: nz4Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by nz4Tg
No data available
GENE EXPRESSION
Gene expression in nz4Tg
PHENOTYPE
Phenotype in nz4Tg
Phenotype Conditions Figures
pronephric distal early tubule havcr1 expression increased amount, abnormal bacterial treatment by injection: Edwardsiella tarda Fig. 3 from Wen et al., 2018
pronephric distal early tubule Ab1-timp2 labeling increased amount, abnormal standard conditions Fig. 3 from Wen et al., 2018
pronephric distal late tubule havcr1 expression increased amount, abnormal bacterial treatment by injection: Edwardsiella tarda Fig. 3 from Wen et al., 2018
pronephric distal late tubule Ab1-timp2 labeling increased amount, abnormal standard conditions Fig. 3 from Wen et al., 2018
pronephric duct Ab2-havcr1 labeling amount, ameliorated chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 3. with image from Skvarca et al., 2019
pronephric duct Ab2-havcr1 labeling increased amount, abnormal chemical treatment by injection: gentamycin Fig. 3. with image from Skvarca et al., 2019
pronephric duct Ab2-havcr1 labeling increased distribution, abnormal chemical treatment by injection: gentamycin Fig. 3. with image from Skvarca et al., 2019
pronephric duct ab2-pcna labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist Fig. 7. with image from Skvarca et al., 2019
pronephric duct ab2-pcna labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 7. with image from Skvarca et al., 2019
pronephric duct ab2-pcna labeling increased distribution, abnormal chemical treatment by injection: gentamycin Fig. 7. with image from Skvarca et al., 2019
pronephric duct Ab2-pax2a labeling increased distribution, abnormal chemical treatment by injection: gentamycin Fig. 1. with image from Skvarca et al., 2019
pronephric duct ab2-pcna labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 7. with image from Skvarca et al., 2019
pronephric duct Ab2-pax2a labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 1. with image from Skvarca et al., 2019
pronephric duct cell population proliferation increased occurrence, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist Fig. 7. with image from Skvarca et al., 2019
pronephric duct cell population proliferation increased occurrence, abnormal chemical treatment by injection: gentamycin Fig. 1. with image from Skvarca et al., 2019
pronephric duct cell population proliferation increased occurrence, ameliorated chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 7. with image from Skvarca et al., 2019
pronephric duct cell population proliferation increased occurrence, exacerbated chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 1. with imageFig. 7. with image from Skvarca et al., 2019
pronephric proximal convoluted tubule havcr1 expression increased amount, abnormal bacterial treatment by injection: Edwardsiella tarda Fig. 3 from Wen et al., 2018
pronephric proximal convoluted tubule igfbp7 expression increased amount, abnormal standard conditions Fig. 3 from Wen et al., 2018
pronephric proximal straight tubule igfbp7 expression increased amount, abnormal standard conditions Fig. 3 from Wen et al., 2018
pronephric proximal straight tubule havcr1 expression increased amount, abnormal bacterial treatment by injection: Edwardsiella tarda Fig. 3 from Wen et al., 2018
pronephric tubule havcr1 expression increased amount, abnormal bacterial treatment by injection: Edwardsiella tarda Fig. 3 from Wen et al., 2018
pronephric tubule brush border epithelial cell decreased thickness, abnormal chemical treatment: pharmaceutical Fig. 1 from Cianciolo Cosentino et al., 2013
pronephric tubule brush border epithelial cell positional polarity, abnormal chemical treatment: pharmaceutical Fig. 1 from Cianciolo Cosentino et al., 2013
regenerating tissue cell population proliferation increased occurrence, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist Fig. 7. with image from Skvarca et al., 2019
regenerating tissue cell population proliferation increased occurrence, abnormal chemical treatment by injection: gentamycin Fig. 1. with image from Skvarca et al., 2019
regenerating tissue cell population proliferation increased occurrence, ameliorated chemical treatment by injection: gentamycin, chemical treatment by environment: retinoic acid receptor antagonist, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 7. with image from Skvarca et al., 2019
regenerating tissue cell population proliferation increased occurrence, exacerbated chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 1. with imageFig. 7. with image from Skvarca et al., 2019
regenerating tissue pronephric duct Ab2-havcr1 labeling decreased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 3. with image from Skvarca et al., 2019
regenerating tissue pronephric duct ab2-pcna labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 1. with imageFig. 7. with image from Skvarca et al., 2019
regenerating tissue pronephric duct Ab2-pax2a labeling increased distribution, abnormal chemical treatment by injection: gentamycin, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 1. with image from Skvarca et al., 2019
renal tubule increased size, abnormal chemical treatment: pharmaceutical Fig. 1 from Cianciolo Cosentino et al., 2013
renal tubule epithelium flattened, abnormal chemical treatment: pharmaceutical Fig. 1 from Cianciolo Cosentino et al., 2013

CITATIONS  (8)